First approval, years of trial data, and patents — in a market rivals have spent decades failing to crack.
↓ scroll to read
✦ The bottom line
Rezdiffra is the first and only FDA- and EMA-approved drug for MASH. That's a powerful moat: doctors default to the proven, approved option; Madrigal has years of clinical data and patents; and MASH defeated many well-funded drug programs before Madrigal succeeded. Being first in a hard, huge market is a real head start.
↓ the brief below
✦ Teach me
Why 'first and only' is a moat
When you're the only approved treatment, you don't just have market share — you are the market. Doctors build experience with your drug, treatment guidelines reference it, and insurers set up coverage around it. A later rival has to dislodge an entrenched standard, not just show up.
Layered on top: patents and the sheer difficulty of MASH (many big companies tried and failed for years) raise the bar for competitors.
Wall Street calls this
First-mover advantage / regulatory exclusivity
It explains why Madrigal can grow so fast and price its drug well — for now. The moat is real, but in a market this big, 'for now' is the operative phrase (Chapter 6).
From the 10-K · the franchise, in Madrigal's words
...commercialize Rezdiffra, our only approved product, in the United States and the European Union for the treatment of metabolic dysfunction-associated steatohepatitis ('MASH') with moderate to advanced liver fibrosis.
↳ Two things in one sentence: the strength (the only approved MASH drug, across the US and EU) and the risk (it's the company's only product). Madrigal's entire value rests on this one franchise — its moat and its concentration are the same fact.
Source · 10-K · Business Overview · FY2025 · Filed Feb 19, 2026
✓
Strong, for now
The only approved drug in a hard, huge market — a genuine first-mover moat. Its durability depends entirely on how fast and how strong competition arrives.